Benchmarking single-arm studies against historical controls from non-small cell lung cancer trials – an empirical analysis of bias

References

• Pikor LA, Ramnarine VR, Lam S, et al. Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer. 2013;82(2):179–189.
   PubMed Web of Science ®Google Scholar
• Jänne PA, Yang J-H, Kim D-W, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372(18):1689–1699.
   PubMed Web of Science ®Google Scholar
• Ng TL, Camidge DR. AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC? Ann Transl Med. 2017;5(S1):S14.
   PubMed Web of Science ®Google Scholar
• Selaru P, Tang Y, Huang B, et al. Sufficiency of single-arm studies to support registration of targeted agents in molecularly selected patients with cancer: lessons from the clinical development of crizotinib. Clin Transl Sci. 2016;9(2):63–73.
   PubMed Web of Science ®Google Scholar
• Simon R, Blumenthal GM, Rothenberg ML, et al. The role of nonrandomized trials in the evaluation of oncology drugs. Clin Pharmacol Ther. 2015;97(5):502–507.
   PubMed Web of Science ®Google Scholar
• Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2009;27(36):6251–6266.
   PubMed Web of Science ®Google Scholar
• Felip E, Gridelli C, Baas P, et al. Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann Oncol. 2011;22(7):1507–1519.
   PubMed Web of Science ®Google Scholar
• Besse B, Adjei A, Baas P, et al. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol. 2014;25(8):1475–1484.
   PubMed Web of Science ®Google Scholar
• Masters GA, Temin S, Azzoli CG, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015;33(30):3488–3515.
   PubMed Web of Science ®Google Scholar
• Kitagawa C, Iwasaku M, Kogure Y, et al. Phase II study of weekly amrubicin for refractory or relapsed non-small cell lung cancer. In Vivo (Athens, Greece). 2019;33(1):163–166.
   PubMed Web of Science ®Google Scholar
• Wu F, Zhang S, Xiong A, et al. A phase II clinical trial of apatinib in pretreated advanced non-squamous non-small-cell lung cancer. Clin Lung Cancer. 2018;19(6):e831–e842.
   PubMed Web of Science ®Google Scholar
• Lee JS, Lee KH, Cho EK, et al. Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy. Lung Cancer. 2018;122:234–242.
   PubMed Web of Science ®Google Scholar
• Sanchez-Meca J, Marin-Martinez F. Confidence intervals for the overall effect size in random-effects meta-analysis. Psychol Methods. 2008;13(1):31–48.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343(2):d5928.
   PubMed Web of Science ®Google Scholar
• Markman M. The dangers of “cross-trial” and “cross-retrospective experience” comparisons: examples employing data in the peer-reviewed ovarian cancer literature. Cancer. 2007;109(10):1929–1932.
   PubMed Web of Science ®Google Scholar
• Lee CK, Lord SJ, Stockler MR, et al. Historical cross-trial comparisons for competing treatments in advanced breast cancer – an empirical analysis of bias. Eur J Cancer (Oxford, England: 1990). 2010;46(3):541–548.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global health observatory (GHO): female life expectancy [Internet]. United Nations. Geneva, Switzerland: World Health Association; c1948–2019; [cited 2019 Apr 19]. Available from: https://www.who.int/gho/women_and_health/mortality/situation_trends_life_expectancy/en/
   Google Scholar
• Oxnard GR, Wilcox KH, Gonen M, et al. Response rate as a regulatory end point in single-arm studies of advanced solid tumors. JAMA Oncol. 2016;2(6):772–779.
   PubMed Web of Science ®Google Scholar
• Jin Y, Sun Y, Shi X, et al. Meta-analysis to assess the efficacy and toxicity of docetaxel-based doublet compared with docetaxel alone for patients with advanced NSCLC who failed first-line treatment. Clin Ther. 2014;36(12):1980–1990.
   PubMed Web of Science ®Google Scholar
• Crequit P, Chaimani A, Yavchitz A, et al. Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis. BMC Med. 2017;15(1):193.
   PubMed Web of Science ®Google Scholar
• Vickers AD, Winfree KB, Cuyun Carter G, et al. Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis. BMC Cancer. 2019;19(1):353.
   PubMed Web of Science ®Google Scholar
• Stroh M, Green M, Cha E, et al. Meta-analysis of published efficacy and safety data for docetaxel in second-line treatment of patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol. 2016;77(3):485–494.
   PubMed Web of Science ®Google Scholar
• Lopez-Chavez A, Thomas A, Rajan A, et al. Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. J Clin Oncol. 2015;33(9):1000–1007.
   PubMed Web of Science ®Google Scholar